Market Insight: Biobetters Gain Momentum as Biologic Innovation Shifts Toward Better Therapeutic Performance

The global biobetters market is entering a stronger phase of expansion, with the market valued at USD 56.4 billion in 2026, expected to reach USD 60.38 billion in 2027 and projected to attain USD 115.92 billion by 2036, reflecting a 7.47% CAGR from 2027 to 2036. The underlying opportunity is increasingly linked to improving established biologics rather than relying exclusively on entirely new therapeutic mechanisms.

Biobetters can address important limitations of existing biologics by improving attributes such as dosing convenience, therapeutic duration, efficacy, or administration. This creates a commercially relevant pathway for pharmaceutical companies seeking to extend the value of established biological therapies while responding to changing treatment expectations.

Patent expirations are an important catalyst. As established biologics face competitive pressure, pharmaceutical companies have greater incentives to develop differentiated alternatives that offer measurable improvements over existing therapies. Increasing pharmaceutical competition is consequently encouraging investment in enhanced-efficacy and next-generation biologic products.

The manufacturing side is also becoming increasingly important. Expanding biologics manufacturing capabilities can improve scalability and support the transition of promising biobetter candidates from development into commercial products. At the same time, technologies enabling longer-acting formulations can reduce administration frequency and potentially improve treatment adherence.

The emergence of oral delivery represents another important direction. Although hospital pharmacies remain central to biobetter distribution because of the controlled handling and monitoring requirements associated with complex biologics, oral approaches can shift portions of treatment toward more convenient settings. This creates opportunities for companies capable of combining biological efficacy with patient-friendly administration.

Regional Analysis: North America Leads While Asia Pacific Builds Development Momentum

North America and Asia Pacific represent two distinct growth models within the biobetters industry. North America maintains the leading regional position because of its mature biologics ecosystem, strong biopharmaceutical presence, established commercialization pathways, and continued investment in improving existing biologic therapies.

The region benefits from an established environment spanning research, clinical development, manufacturing, healthcare institutions, and commercialization. This ecosystem supports the development of sophisticated biologic modifications and provides pharmaceutical companies with established pathways for bringing differentiated therapies into clinical use.

Asia Pacific, by contrast, is positioned as the high-growth regional hub, with a 9.38% CAGR. Its momentum is associated with expanding biopharmaceutical R&D, strengthening manufacturing capabilities, and increasing development of next-generation biologic products.

Regional position	Key characteristics	Strategic implication
North America	Mature biologics ecosystem, strong biopharma presence, established commercialization pathways	Supports advanced development and commercialization of differentiated biobetters
Asia Pacific	Expanding R&D, strengthening manufacturing, growing next-generation biologics development	Creates opportunities for development, manufacturing, and regional market expansion

The contrast suggests that market opportunities are not concentrated in a single stage of the value chain. North America provides a strong environment for advanced innovation and commercialization, while Asia Pacific offers expanding capabilities for research and manufacturing. Companies operating internationally can therefore consider different regional strengths when structuring development and commercialization strategies.

Industry Challenge: Commercializing Biobetters Requires More Than Incremental Product Improvement

One of the central challenges for biobetter developers is demonstrating sufficient differentiation from established biologics. Improving an existing therapy can create a strong scientific proposition, but commercial adoption depends on whether the improvement translates into meaningful value for healthcare providers and patients.

This challenge is particularly relevant when competing against established treatment pathways. Hospital pharmacies remain a dominant distribution channel because biologics often require controlled handling, specialist-led treatment, coordinated administration, and patient monitoring. Such infrastructure can support adoption, but it can also make the transition to alternative products more complex.

Administration remains another critical consideration. Subcutaneous delivery can provide a more convenient alternative to certain administration approaches, while oral delivery is expanding because it can reduce administration burden and improve convenience outside clinical settings. However, moving toward easier administration requires developers to address formulation and biological-performance requirements without compromising therapeutic outcomes.

Manufacturing scalability is an additional commercial constraint. A promising biobetter must ultimately be supported by reliable production capabilities capable of meeting commercial requirements. The expanding biologics manufacturing ecosystem therefore represents both an opportunity and a competitive requirement.

For industry participants, the challenge is consequently broader than creating an improved molecule. Successful commercialization requires alignment among clinical differentiation, administration convenience, manufacturing scalability, distribution infrastructure, and commercialization strategy.

Product and Segment Comparison: Hospital Pharmacies Versus Online Pharmacies

Distribution channels illustrate how the biobetters market is balancing complex biologic handling requirements with increasing demand for treatment convenience.

Hospital pharmacies currently represent the core distribution channel. Their importance stems from the controlled handling of biologics, specialist-led treatment pathways, coordinated administration, and the need for ongoing patient monitoring. This makes institutional settings particularly relevant for complex therapies that require healthcare professional involvement.

Online pharmacies, meanwhile, represent an emerging opportunity. Their relevance is connected to the broader shift toward convenient treatment access and potentially less institution-dependent medication fulfillment. As therapies become easier to administer, digital distribution channels can become more compatible with patient-centered treatment models.

Factor	Hospital Pharmacies	Online Pharmacies
Primary role	Controlled distribution and administration support	Convenient medication access
Key strength	Specialist oversight and coordinated treatment	Accessibility and convenience
Market position	Core revenue segment	Emerging opportunity
Strategic relevance	Complex biologic therapies	More convenient treatment pathways

The distinction is not necessarily a replacement of one channel by another. Instead, channel relevance can evolve alongside product design. Complex biologics requiring specialist oversight are likely to remain closely connected with institutional channels, while biobetters designed around easier administration may create additional opportunities for online fulfillment.

Geographic Opportunity: Four Markets Connected to the Biobetters Expansion

United States

The United States is strategically important because it forms part of North America's mature biologics ecosystem and has a strong biopharmaceutical presence. Established commercialization pathways and continued investment in biologic therapies create a favorable environment for companies developing differentiated products.

China

China represents an important Asia Pacific opportunity as the region expands biopharmaceutical R&D and strengthens manufacturing capabilities. Its relevance is particularly connected to the broader development of next-generation biologic products across Asia Pacific.

Japan

Japan is strategically relevant to the biobetters landscape through its established pharmaceutical industry and presence of major participants such as Takeda Pharmaceutical Company. The country's pharmaceutical capabilities provide an established base for participation in advanced biologic development.

India

India represents an emerging strategic opportunity within the broader Asia Pacific growth story. Expansion of regional biopharmaceutical capabilities can support increasing participation in biologics development and manufacturing, particularly as the industry places greater emphasis on scalable production and next-generation therapies.

Across these markets, the opportunity differs according to ecosystem maturity and manufacturing development. North American markets are closely associated with established commercialization infrastructure, while Asian markets are increasingly important to the industry's R&D and manufacturing expansion.

Competitive Landscape: Partnerships and Licensing Reshape Biobetter Development Strategies

The competitive landscape is increasingly characterized by partnerships, licensing agreements, technology collaborations, and pipeline expansion. These strategies allow pharmaceutical companies to access specialized technologies or promising candidates while accelerating the development of next-generation biologics.

Major participants include F. Hoffmann-La Roche, Novartis, AbbVie, Johnson & Johnson, Merck & Co., Pfizer, Bristol-Myers Squibb, Sanofi, AstraZeneca, and Takeda Pharmaceutical Company. Their presence reflects the strategic importance of biologic innovation across major pharmaceutical portfolios.

Recent transactions also demonstrate several distinct strategic approaches. XL-protein GmbH's launch of PASYIANTA Therapeutics in May 2026 established a focused entity for long-acting IL-1Ra biobetters, highlighting the importance of therapeutic duration and engineered proteins.

In June 2025, BioNTech and Bristol Myers Squibb entered a global partnership valued at up to USD 9.1 billion to co-develop and commercialize the bispecific antibody BNT327. The collaboration demonstrates how companies are combining capabilities to advance complex oncology biologics.

Eli Lilly's June 2025 agreement with Camurus, valued at up to USD 870 million, focused on long-acting GLP-1 and incretin therapies using FluidCrystal technology. The development highlights administration and duration as important dimensions of biobetter innovation.

Meanwhile, licensing is another route to portfolio expansion. Hansoh Pharmaceutical granted Regeneron worldwide rights to HS-20094 in June 2025, while AbbVie licensed FG-M701 from FutureGen in June 2024. These developments indicate that competitive positioning increasingly depends not only on internal R&D but also on accessing external innovation.

Recent Industry News: Partnerships Accelerate the Next Wave of Biobetter Development

Recent developments across the industry point toward a market increasingly focused on long-acting therapies, engineered proteins, targeted biologics, and technology-enabled improvements in treatment delivery.

• May 2026 – XL-protein GmbH: XL-protein launched PASYIANTA Therapeutics as a spin-off focused on long-acting IL-1Ra biobetters. The move strengthens its focus on engineered proteins designed to improve therapeutic duration and patient outcomes.
• June 2025 – BioNTech and Bristol Myers Squibb: The companies formed a global partnership valued at up to USD 9.1 billion to co-develop and commercialize BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid tumors. The agreement illustrates the growing role of collaborative development in advanced biologics.
• June 2025 – Eli Lilly and Camurus: Eli Lilly entered an agreement valued at up to USD 870 million for the development of long-acting GLP-1 and incretin therapies using FluidCrystal technology. The collaboration emphasizes extended-release delivery and therapeutic durability.
• June 2025 – Hansoh Pharmaceutical and Regeneron: Hansoh granted Regeneron worldwide rights to HS-20094 under an agreement valued at up to USD 1.93 billion in milestones. The transaction expands commercialization pathways for next-generation metabolic biologics.
• June 2024 – Arrivent Biopharma and Alphamab Biopharmaceuticals: The companies signed an antibody-drug conjugate collaboration potentially worth USD 615.5 million, supporting next-generation biologic development in targeted oncology.
• June 2024 – AbbVie and FutureGen: AbbVie licensed FG-M701, a next-generation TL1A antibody for inflammatory bowel disease, under an agreement worth USD 150 million upfront and up to USD 1.56 billion in milestones. The transaction demonstrates continued pharmaceutical interest in differentiated biologic candidates.

Read more about this report @ https://www.fundamentalbusinessinsights.com/industry-report/biobetters-market-14822

About

Fundamental Business Insights:

Fundamental Business Insights is global market research and consulting company which is engaged in providing in depth market reports to its various types of clients like industrial sectors, financial sectors, universities, non-profit, and corporations. Our goal is to offer the correct information to the right stakeholder at the right time, in a format that enables logical and informed decision making. We have a team of consultants who have experience in offering executive level blueprints of markets and solutions. Our services include syndicated market studies, customized research reports, and consultation.

Contact us:
Robbin Fernandez
Head of Business Development
Fundamental Business Insights and Consulting
Email:  sales@fundamentalbusinessinsights.com

Read This Report in Regional Languages - 

https://www.fundamentalbusinessinsights.com/ko/industry-report/biobetters-market-14822

https://www.fundamentalbusinessinsights.com/ja/industry-report/biobetters-market-14822

https://www.fundamentalbusinessinsights.com/de/industry-report/biobetters-market-14822

https://www.fundamentalbusinessinsights.com/it/industry-report/biobetters-market-14822

https://www.fundamentalbusinessinsights.com/es/industry-report/biobetters-market-14822

https://www.fundamentalbusinessinsights.com/fr/industry-report/biobetters-market-14822